Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study.

Paul P Dobesh,Gregory J Fermann,Mary J Christoph,Bruce Koch,Eva Lesén,Hungta Chen,Belinda Lovelace, Theresa Dettling, Mark Danese,Julie Ulloa, Sherry Danese,Craig I Coleman

Research and practice in thrombosis and haemostasis（2023）

引用 0|浏览5

暂无评分

摘要

In this large observational study, treatment with andexanet alfa in patients hospitalized with rivaroxaban- or apixaban-related major bleeds was associated with 50% lower odds of in-hospital mortality than 4F-PCC. The magnitude of the risk reduction was similar in ICH and GI bleeds.

查看译文

关键词

major bleeding,prothrombin complex concentrate,andexanet alfa,inhibitor-related,hospital-based

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要